Baldwin, AG;
Rivers-Auty, J;
Daniels, MJD;
White, CS;
Schwalbe, CH;
Schilling, T;
Hammadi, H;
Jaiyong, P;
Spencer, NG;
England, H;
et al.
Baldwin, AG; Rivers-Auty, J; Daniels, MJD; White, CS; Schwalbe, CH; Schilling, T; Hammadi, H; Jaiyong, P; Spencer, NG; England, H; Luheshi, NM; Kadirvel, M; Lawrence, CB; Rothwell, NJ; Harte, MK; Bryce, RA; Allan, SM; Eder, C; Freeman, S; Brough, D
(2017)
Boron-Based Inhibitors of the NLRP3 Inflammasome.
Cell Chem Biol, 24 (11).
1321-1335.e5.
ISSN 2451-9456
https://doi.org/10.1016/j.chembiol.2017.08.011
SGUL Authors: Eder, Claudia
Abstract
NLRP3 is a receptor important for host responses to infection, yet is also known to contribute to devastating diseases such as Alzheimer's disease, diabetes, atherosclerosis, and others, making inhibitors for NLRP3 sought after. One of the inhibitors currently in use is 2-aminoethoxy diphenylborinate (2APB). Unfortunately, in addition to inhibiting NLRP3, 2APB also displays non-selective effects on cellular Ca2+ homeostasis. Here, we use 2APB as a chemical scaffold to build a series of inhibitors, the NBC series, which inhibit the NLRP3 inflammasome in vitro and in vivo without affecting Ca2+ homeostasis. The core chemical insight of this work is that the oxazaborine ring is a critical feature of the NBC series, and the main biological insight the use of NBC inhibitors led to was that NLRP3 inflammasome activation was independent of Ca2+. The NBC compounds represent useful tools to dissect NLRP3 function, and may lead to oxazaborine ring-containing therapeutics.
Statistics
Item downloaded times since 01 Dec 2017.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |